InvestorsHub Logo
Followers 261
Posts 19732
Boards Moderated 0
Alias Born 10/03/2004

Re: TheBunny post# 28128

Wednesday, 02/24/2010 4:45:03 PM

Wednesday, February 24, 2010 4:45:03 PM

Post# of 146240
RE: What's up Doc?

My portfolio, that's what.

Obviously, Agora is helping put renewed buying pressure, but the news of the Dengue study certainly has had legs. Good results there and it will get the attention of the military and the CDC as both are focused on that disease. However, one of Dr. Harris's many contacts could take DengueCide into the field and prescribe it for compassionate use in any one of a dozen Central South or Caribbean nations with high numbers of infections.

No, I'm not saying that this would happen, after all humans would require 100 times the amount of material, and that material will be needed just for pre-IND and Phase-1 testing which would alone tax the output of the expanded facility to its limit. (my understanding of its capacity)

However, the path to that IND filing and Phase 1 test just got shorter because of Harris and Berkeley, even if the indication chosen is not Dengue. She brings tremendous credibility to NNVC's technology, credibility not shared even by SRI. So, many now know, and many more are learning of her, and success in her labs will lend tremendous support to other studies such as HIV, HSV and Influenza. On top of that, Harris has a reputation for fast, accurate and reliable testing: very fast, very accurate and very reliable.

Maybe other things going on, but...I can't say.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NNVC News